8-K: Aptose Shareholders Approve Hanmi Acquisition & Continuance

Aptose Biosciences shareholders overwhelmingly approved the plan of arrangement for acquisition by Hanmi Pharmaceutical and a corporate continuance to Alberta.

Summary

• Aptose Biosciences Inc. held a Special Meeting of shareholders on March 31, 2026, where all items of business were approved.
• Shareholders voted in favor of the Continuance Resolution, approving the continuation of the Corporation from the Canada Business Corporations Act (CBCA) to the Business Corporations Act (Alberta) with 92.42% of votes for.
• Shareholders also approved the Arrangement Resolution, allowing HS North America Ltd., a wholly-owned subsidiary of Hanmi Pharmaceutical Co. Ltd., to acquire all issued and outstanding common shares not currently owned or controlled by the Hanmi Purchasers or their affiliates, with 84.87% of votes for.
• The plan of arrangement was previously announced on November 19, 2025, and February 24, 2026.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a positive development, as shareholder approval for both the corporate continuance and the acquisition by Hanmi Pharmaceutical indicates successful progression of strategic initiatives and a clear path forward for the company.

Positives

• Shareholders demonstrated strong support by approving both the corporate continuance and the acquisition plan with high percentages (92.42% and 84.87% respectively).
• The successful vote indicates a clear path forward for the company's strategic initiatives, including the planned acquisition.

Future Outlook

The approval of the Arrangement Resolution by shareholders paves the way for the acquisition of Aptose Biosciences by HS North America Ltd., a subsidiary of Hanmi Pharmaceutical Co. Ltd., indicating the transaction is moving forward towards completion.

Industry Context

StockSavvy.ai notes that consolidation through acquisitions is a common trend in the biotechnology and pharmaceutical sectors, driven by the need for expanded pipelines, market access, and operational efficiencies. This acquisition by Hanmi Pharmaceutical aligns with this trend, potentially allowing Aptose's assets to be further developed under a larger entity.

Corporate Governance

Stakeholder Impact

• Shareholders: Existing shareholders will have their shares acquired by HS North America Ltd. as part of the arrangement, leading to a change in ownership.
• Employees: While not explicitly stated, acquisitions often lead to integration efforts that can impact employee roles and structures.

Next Steps

• Completion of the corporate continuance from the Canada Business Corporations Act to the Business Corporations Act (Alberta).
• Finalization of the plan of arrangement for the acquisition of Aptose Biosciences by HS North America Ltd.

Key Dates

Recommendation

The overwhelming shareholder approval of the acquisition by Hanmi Pharmaceutical suggests the transaction is on track to close. For existing shareholders, holding shares until the acquisition is finalized is the logical next step to realize the agreed-upon acquisition value. New investors would need to assess the premium, if any, remaining in the stock price relative to the acquisition terms.

Keywords

Aptose Biosciences, Hanmi Pharmaceutical, Acquisition, Shareholder Vote, Arrangement Resolution, Continuance Resolution, Biotechnology, Merger, Corporate Governance